Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04687423 | Study of FCN-011 in Patients With Advanced Solid Tumor（Phase I）and NTRK Fusion Positive Advanced Solid Tumor （Phase II） | unknown | Phase 1 | 82 | Fochon Pharmaceuticals, Ltd.INDUSTRY | 1 | Aug 18, 2021 | clinicaltrials |
| NCT03374007 | Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma(GB226) | unknown | Phase 1 | 72 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Aug 16, 2021 |
| clinicaltrials |
| NCT04267575 | Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites | unknown | N/A | 20 | Jerome Canady, M.D.OTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT04989010 | Safety Study of 89Zr-Anti-CLDN18.2 mAbs PET Imaging in Patients With CLDN18.2 Positive Solid Tumors | unknown | N/A | 20 | Wuxi No. 4 People's HospitalOTHER | 1 | Aug 4, 2021 | clinicaltrials |
| NCT04802980 | A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor | unknown | Phase 1 | 72 | Huabo Biopharm Co., Ltd.INDUSTRY | 1 | Jul 28, 2021 | clinicaltrials |
| NCT04871347 | The Safety and Efficacy of TWP-101 in Patients With Advanced Solid Tumor | unknown | Phase 1 | 58 | Shandong TheraWisdom Biopharma Co., Ltd.INDUSTRY | 1 | Jul 27, 2021 | clinicaltrials |
| NCT04971369 | Safety Study of 89Zr-NY001 PET Imaging in Patients | unknown | N/A | 20 | Wuxi No. 4 People's HospitalOTHER | 1 | Jul 27, 2021 | clinicaltrials |
| NCT04977128 | 89Zr-labeled KN035 PET Imaging in Patients With PD-L1 Positive Solid Tumors | unknown | N/A | 20 | Wuxi No. 4 People's HospitalOTHER | 1 | Jul 26, 2021 | clinicaltrials |
| NCT04237805 | A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients | unknown | Phase 1 / Phase 2 | 280 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Jul 8, 2021 | clinicaltrials |
| NCT04937842 | Microtransplantation for Advanced and Relapsed Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Jun 24, 2021 | clinicaltrials |
| NCT04905329 | A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations(Def_Special) | unknown | — | 285 | Moscow Clinical Scientific CenterOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04906473 | Safety,Tolerability, Pharmacokinetic,Pharmacodynamics and Efficacy of KY100001 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 109 | Kunming Pharmaceuticals, Inc.INDUSTRY | 0 | May 28, 2021 | clinicaltrials |
| NCT04556669 | Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors | unknown | Phase 1 | 30 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | May 27, 2021 | clinicaltrials |
| NCT04890587 | A Phase I Study of AL8326 in Advanced Solid Tumor | unknown | Phase 1 | 40 | Advenchen Laboratories Nanjing Ltd.INDUSTRY | 1 | May 18, 2021 | clinicaltrials |
| NCT04891653 | A Phase I Study of BR790 in Subjects With Advanced Solid Tumors | unknown | Phase 1 | 48 | Jiangxi Qingfeng Pharmaceutical Co. Ltd.INDUSTRY | 0 | May 18, 2021 | clinicaltrials |
| NCT04337463 | ATG-008 Combined With Toripalimab in Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Sichuan UniversityOTHER | 1 | May 17, 2021 | clinicaltrials |
| NCT04869475 | Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation | unknown | Phase 2 | 20 | Ruijin HospitalOTHER | 1 | May 13, 2021 | clinicaltrials |
| NCT03552406 | Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 33 | ISU Abxis Co., Ltd.INDUSTRY | 1 | May 6, 2021 | clinicaltrials |
| NCT04873440 | An Open-label, Phase I/II Study of Manganese Plus Radiotherapy in Patients With Metastatic Solid Tumors or Lymphoma | unknown | Phase 1 / Phase 2 | 10 | Chinese PLA General HospitalOTHER | 1 | May 5, 2021 | clinicaltrials |
| NCT03852823 | Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours | unknown | Phase 1 | 192 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Apr 30, 2021 | clinicaltrials |
| NCT04866485 | A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody | unknown | Phase 1 | 66 | Harbour BioMed (Guangzhou) Co. Ltd.INDUSTRY | 0 | Apr 29, 2021 | clinicaltrials |
| NCT02435927 | ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin | unknown | Phase 1 | 60 | National Cancer Centre, SingaporeOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT04864379 | Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors | unknown | Phase 1 | 30 | Sir Run Run Shaw HospitalOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT04758897 | Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors | unknown | Phase 1 | 18 | CNBG-Virogin Biotech (Shanghai) Ltd.INDUSTRY | 1 | Apr 27, 2021 | clinicaltrials |
| NCT04843033 | A Study to Investigate Safety and Tolerability of SH3809 Tablet in Patients With Advanced Solid Tumors | unknown | Phase 1 | 55 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Apr 13, 2021 | clinicaltrials |
| NCT04841421 | Clinical Study on PET Imaging, Distribution and PK of 89Zr-CD147 in Patients With Solid Tumors | unknown | Early Phase 1 | 30 | Sinotau Pharmaceutical GroupINDUSTRY | 0 | Apr 12, 2021 | clinicaltrials |
| NCT04832204 | Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases | unknown | Phase 2 | 20 | Beijing HospitalOTHER_GOV | 1 | Apr 5, 2021 | clinicaltrials |
| NCT04675060 | Effect of High-fat Meal on the Pharmacokinetics of TQ-B3139 Capsules | unknown | Phase 1 | 12 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 1, 2021 | clinicaltrials |
| NCT04825392 | A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Apr 1, 2021 | clinicaltrials |
| NCT04175899 | Effectiveness of Pharmacist Intervention on Capecitabine Relative Dose Intensity, Adherence, Knowledge & Safety Among Cancer Patients in Malaysia(POCCP1) | unknown | N/A | 106 | Ministry of Health, MalaysiaOTHER_GOV | 1 | Mar 8, 2021 | clinicaltrials |
| NCT03704246 | Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors | unknown | Phase 2 | 123 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Mar 4, 2021 | clinicaltrials |
| NCT04773808 | Molecular Characterization of Genetic Alterations in Pediatric Solid Tumors | unknown | — | 100 | National Council of Scientific and Technical Research, ArgentinaOTHER_GOV | 1 | Feb 26, 2021 | clinicaltrials |
| NCT04761744 | A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers | unknown | Phase 2 | 48 | Korean Cancer Study GroupOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT02500199 | Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors | unknown | Phase 1 | 50 | Hengrui Therapeutics, Inc.INDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
| NCT04727164 | Study Investigating Safety,Tolerability,Pharmacokinetics and Antitumor Activities of HBM4003 Combine With Toripalimab | unknown | Phase 1 | 61 | Harbour BioMed (Guangzhou) Co. Ltd.INDUSTRY | 0 | Jan 29, 2021 | clinicaltrials |
| NCT04699643 | FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 80 | EverNov Medicines (Zhuhai Hengqin) Co., LtdINDUSTRY | 1 | Jan 7, 2021 | clinicaltrials |
| NCT04325711 | A Study of CSPCHA131 in Patients With Advanced Solid Tumor | unknown | Phase 1 | 100 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jan 6, 2021 | clinicaltrials |
| NCT04691713 | CD276 CAR-T for Patients With Advanced CD276+ Solid Tumors | unknown | N/A | 5 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 31, 2020 | clinicaltrials |
| NCT04689100 | Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor | unknown | Phase 1 | 259 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Dec 30, 2020 | clinicaltrials |
| NCT04673396 | Phase I Clinical Study for Evaluation of Pharmacokinetic, Safety, Tolerance of Norcantharidin Lipid Microsphere for Injection in Patients With Solid Tumor | unknown | Phase 1 | 36 | Beijing Nuokangda Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT04226066 | Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors | unknown | Phase 1 / Phase 2 | 69 | Tasly Tianjin Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 7, 2020 | clinicaltrials |
| NCT04647838 | Tepotinib in Solid Tumors Harboring MET Alterations | unknown | Phase 2 | 100 | Chungbuk National University HospitalOTHER | 1 | Dec 2, 2020 | clinicaltrials |
| NCT04478461 | Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 21 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04623892 | A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2618 Injection in Subjects With Advanced Solid Tumors | unknown | Phase 1 | 50 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Nov 10, 2020 | clinicaltrials |
| NCT04262739 | MTD, Safety and Efficacy of NYH817G and NYH100P in Monotherapy and Combination in Patients With Advanced Solid Tumors | unknown | Phase 1 | 42 | Haim Bio Co., Ltd.INDUSTRY | 1 | Oct 20, 2020 | clinicaltrials |
| NCT04588324 | Study of SHR2150 (TLR7 Agonist) in Combination With Chemotherapy Plus PD-1 or CD47 Antibody in Subjects With Unresectable/ Metastatic Solid Tumors | unknown | Phase 1 / Phase 2 | 50 | Chinese PLA General HospitalOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT04569916 | Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors | unknown | Phase 2 | 30 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Sep 30, 2020 | clinicaltrials |
| NCT04550663 | NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors | unknown | Phase 1 | 10 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Sep 23, 2020 | clinicaltrials |
| NCT03998345 | Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A in China | unknown | N/A | 24 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.INDUSTRY | 1 | Sep 9, 2020 | clinicaltrials |
| NCT03545815 | Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors. | unknown | Phase 1 | 10 | Chinese PLA General HospitalOTHER | 1 | Aug 10, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Aug 18, 2021source: clinicaltrials